EMEA-001631-PIP01-14-M04 - paediatric investigation plan
Letermovir
PIPHuman
Merck Sharp & Dohme (Europe), Inc.
Tel. +33 180464738
E-mail: pip.information@merck.com
P/0362/2019: EMA decision of 4 November 2019 on the acceptance of a modification of an agreed paediatric investigation plan for letermovir (Prevymis), (EMEA-001631-PIP01-14-M04)